Editing Survival Statistics (section)

== What Is the Prognosis for Peritoneal Mesothelioma with CRS-HIPEC? ==

Cytoreductive surgery with heated intraperitoneal chemotherapy (CRS-HIPEC) has transformed peritoneal mesothelioma from universally fatal to potentially curable in selected patients.<ref>[https://mesothelioma.net/heated-intraperitoneal-chemotherapy/ Heated Intraperitoneal Chemotherapy (HIPEC)], Mesothelioma.net</ref>

The completeness of cytoreduction represents the paramount prognostic factor:<ref>[https://dandell.com/mesothelioma-lawyers/ Top-Rated Mesothelioma Lawyers], Danziger & De Llano</ref>

* '''CC-0 (Complete Cytoreduction):''' 104 months median survival
* '''CC-1 (Minimal Residual):''' 30 months median survival
* '''CC-2 (Incomplete):''' 2.7 months median survival

Peritoneal Cancer Index (PCI), measuring tumor distribution across abdominal regions, also strongly predicts outcomes:<ref>[https://www.mesotheliomalawyercenter.org/mesothelioma-cancer/ Mesothelioma Cancer], Mesothelioma Lawyer Center</ref>

* '''PCI 0-20:''' 103 months median survival
* '''PCI 21-39:''' 33 months median survival

The 2025 PSM Consortium Consensus Guidelines emphasize complete cytoreduction as the treatment goal, with cisplatin plus doxorubicin emerging as the preferred HIPEC regimen (53 months mean survival versus 38 months with single agents).<ref>[https://mesothelioma.net/peritonectomy/ Peritonectomy/Cytoreductive Surgery], Mesothelioma.net</ref>

Australian single-center data demonstrates 53 months median survival and 49% 5-year survival, while conditional survival analysis shows patients surviving 3 years post-surgery achieve 6.1 years median additional survival.<ref>[https://mesotheliomaattorney.com/mesothelioma/types/peritoneal/ Peritoneal Mesothelioma], Mesothelioma Attorney</ref>